Inhaled dehydroepiandrosterone-3-sulfate (DHEAS), but not dehydroepiandrosterone (DHEA), possesses anti-inflammatory activity in in vitro assays and in models of allergen and lipopolysaccharide challenges. We postulated whether an inhaled suspension of DHEAS delivered via nebulizer would improve asthma control in moderate-to-severe asthma patients. We also characterized the safety profile of an inhaled suspension of DHEAS. Patients receiving at least 500 μg of fluticasone equivalent plus long-acting beta-agonists (LABA) entered a 5-week run-in where the dose of inhaled corticosteroids was reduced to 200 μg of fluticasone plus LABA per day. Patients were randomized to 70 mg of DHEAS or placebo if their Asthma Control Questionnaire (ACQ) score was ≥2.0 and their FEV(1) ≥ 50%. When compared with control, a statistically significant improvement in ACQ in 6 weeks of treatment with 70 mg of DHEAS was observed. The median improvement in ACQ was -0.72 and -0.43 for the active and placebo groups, respectively (p = 0.0389); the percentage of patients with at least minimally clinically important difference of -0.50 from baseline was significantly greater in the DHEAS group versus the placebo, (59.4% versus 45.7%; p = 0.0236). Asthma symptom scores, the proportion of symptom-free days and symptom nights, although not statistically significant, had positive trends supporting the improvement in ACQ. Fewer patients were withdrawn from the study for respiratory events on DHEAS compared with placebo. There were few adverse events and no changes in sex hormones despite increases in circulating levels of DHEAS. An inhaled suspension of DHEAS delivered via nebulizer improved asthma control scores in subjects with poorly controlled moderate-to-severe asthma. AUSTRALIAN NEW ZEALAND CLINICAL TRIALS REGISTRY ANZCTR.ORG.AU IDENTIFIER: 012607000192482.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2500/aap.2010.31.3384 | DOI Listing |
Monaldi Arch Chest Dis
January 2025
Department of Respiratory Medicine, N.K.P. Salve Institute of Medical Sciences and Research Center, Lata Mangeshkar Hospital, Nagpur, Maharashtra.
Asthma is a heterogeneous disease characterized by chronic airway inflammation. It is defined by the history of respiratory symptoms such as wheeze, shortness of breath, chest tightness, and cough that vary over time and intensity, together with variable expiratory airflow limitation. A personal history or a family history of allergy is the factor most strongly associated with the development of asthma.
View Article and Find Full Text PDFBMC Pulm Med
January 2025
Global Health and Infectious Diseases Control Institute, Nasarawa State University, Keffi, Nigeria.
Background: Cannabis is the third most widely used psychoactive substance globally, and its consumption has been increasing, particularly with the growing trend of legalization for medicinal and recreational use. Recent studies have raised concerns about the potential impact of cannabis on respiratory health, specifically the risk of asthma, a significant public health concern. This systematic review aimed to consolidate research on the association between cannabis use and the risk of asthma.
View Article and Find Full Text PDFNiger Med J
January 2025
Health Sciences Research and Innovation Laboratory Medical School of Medicine & Pharmacy of Agadir, Ibn Zohr University, Agadir-Morocco.
Background: Asthma is a common chronic disease, and asthma control is the major therapeutic objective, thus ensuring a good health-related quality of life. This study aimed to evaluate the level of asthma control in a sample of asthmatic patients followed in allergology consultation during our training using the asthma control test (ACT) and its correlation with other parameters.
Methodology: This is a cross-sectional study of 66 asthmatic patients who were followed in pulmonology consultation at Agadir University Hospital after completing the asthma control test questionnaire over 6 months (June to December 2021).
Allergy Asthma Clin Immunol
January 2025
Allergy Research Unit, Kingston Health Sciences Center - KGH Site, Kingston, ON, Canada.
J Asthma
January 2025
Division of Respiratory Medicine and Allergology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.
Persistent cough bothers many patients with asthma because it worsens their quality of life; therefore, it must be remedied immediately. The efficacy of triple therapy as a first-line treatment for cough remains unclear. To evaluate the effectiveness and safety of the triple therapy againts persistent cough, the clinical effect of regular treatment with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) or placebo in adult patients with asthma was investigated.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!